AVEO and Astellas terminate global collaboration and license agreement for the development and commercialization of Tivozanib
[ad_1] CAMBRIDGE, Massachusetts and TOKYO – (COMMERCIAL THREAD) – AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced today that the companies will end their global collaboration and license agreement for the development and commercialization of the agent experimental tivozanib. Tivozanib is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth […]